Abstract: The present invention provides a half-life extension drug and a library thereof, and a preparation method and application thereof. Specifically, the present invention provides a drug library, comprising: (a) a drug unit; and (b) n half-life extension units, wherein the drug unit comprises a drug element portion and a first nucleic acid element portion connected to the drug element portion, and each half-life extension unit comprises a half-life extension element portion and a second nucleic acid element portion connected to the half-life extension element portion. Moreover, one first nucleic acid element portion of the drug unit and the second nucleic acid element portion of the at least one half-life extension unit may form a “drug unit-half-life extension unit” complex by forming a complementary base pairing structure, and n is a positive integer greater than or equal to 1.

Abstract: Provided are a multispecific protein drug and a library thereof, a preparing method therefor and an application thereof. Specifically, a protein drug library is provided and comprises C different protein drug monomers, wherein the protein drug monomer comprises a protein drug component part and a nucleic acid component part connected with the protein drug component part, and the nucleic acid component part of one protein drug monomer establishes a double-stranded paired structure with a nucleic acid component part of at least one different protein drug monomer by means of complementation, thereby constituting a protein drug polymer, wherein C is a positive integer greater than or equal to 2.

Abstract: Provided are a multispecific protein drug and a library thereof, a preparing method therefor and an application thereof. Specifically, a protein drug library is provided and comprises C different protein drug monomers, wherein the protein drug monomer comprises a protein drug component part and a nucleic acid component part connected with the protein drug component part, and the nucleic acid component part of one protein drug monomer establishes a double-stranded paired structure with a nucleic acid component part of at least one different protein drug monomer by means of complementation, thereby constituting a protein drug polymer, wherein C is a positive integer greater than or equal to 2.

Abstract: Disclosed are an rTRAIL mutant and monomethyl auristatin E (MMAE) conjugate thereof. The amino acid sequence thereof is as represented by SEQ ID No.1. Also disclosed are a coding gene of the rTRAIL mutant and expression system, recombinant vector and expression unit containing the coding gene. Also disclosed are an rTRAIL mutant-vcMMAE conjugate and preparation and uses thereof. The conjugate of the present invention has the biological functions of both the rTRAIL mutant and the MMAE; the MMAE is directionally transferred to a tumor cell through the specific binding between the rTRAIL mutant and a death receptor on the surface of the tumor cell, and is released and takes effect in the tumor cell, thus killing the tumor cells less sensitive or even resistant to TRAIL, and reducing the toxicity generated by the separate administration of the MMAE.

Abstract: Disclosed are an rTRAIL mutant and monomethyl auristatin E (MMAE) conjugate thereof. The amino acid sequence thereof is as represented by SEQ ID No.1. Also disclosed are a coding gene of the rTRAIL mutant and expression system, recombinant vector and expression unit containing the coding gene. Also disclosed are an rTRAIL mutant-vcMMAE conjugate and preparation and uses thereof. The conjugate of the present invention has the biological functions of both the rTRAIL mutant and the MMAE; the MMAE is directionally transferred to a tumor cell through the specific binding between the rTRAIL mutant and a death receptor on the surface of the tumor cell, and is released and takes effect in the tumor cell, thus killing the tumor cells less sensitive or even resistant to TRAIL, and reducing the toxicity generated by the separate administration of the MMAE.